Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Larimar Therapeutics ( (LRMR) ) has provided an update.
On July 29, 2025, Larimar Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC and Guggenheim Securities, LLC for the sale of 18,750,000 shares of common stock at $3.20 per share. The underwriters exercised their option to purchase an additional 2,812,500 shares, bringing the total expected net proceeds to $64.4 million. The offering, managed by multiple financial firms, is set to close on July 31, 2025, pending customary conditions, and aims to strengthen the company’s financial position.
The most recent analyst rating on (LRMR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.
Spark’s Take on LRMR Stock
According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.
Larimar Therapeutics’ stock score reflects its early-stage biotech status with high R&D costs, no consistent revenue, and reliance on equity financing. Despite positive short-term technical indicators suggesting upward momentum, the lack of profitability and a negative P/E ratio weigh heavily on the stock. Valuation concerns and the absence of earnings call insights further impact the score.
To see Spark’s full report on LRMR stock, click here.
More about Larimar Therapeutics
Larimar Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of treatments for rare diseases. The company primarily engages in the research and development of therapeutic products aimed at addressing unmet medical needs in the market.
Average Trading Volume: 1,277,711
Technical Sentiment Signal: Sell
Current Market Cap: $226M
See more data about LRMR stock on TipRanks’ Stock Analysis page.